Virios Therapeutics, Inc.

  • About Virios
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Corporate Presentation
  • Target Diseases
    • Fibromyalgia
    • Long Covid
    • Blog
  • Pipeline
    • Pipeline
    • Presentations and Publications
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • News

  • Press Releases
  • Email Alerts
Jan 04, 2021 4:05pm EST

Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Dec 21, 2020 3:00pm EST

Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-Allotment Option

Dec 16, 2020 6:16pm EST

Virios Therapeutics Announces Pricing of Initial Public Offering

Apr 05, 2020 12:00am EDT

Virios Therapeutics (Formerly Innovative Med Concepts) Builds Out Leadership Team to Scale Capital and Prepare to Execute Landmark IMC-1 Phase 2b Fibromyalgia Program

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2023 Virios Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines